# OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

Study · id `cardio:ct-nct04789239` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04789239](<https://clinicaltrials.gov/study/NCT04789239>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04789239

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT04789239. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT04789239, source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)
- Started: 2021-09-01 (actual) (ClinicalTrials.gov record NCT04789239, source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04789239, source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT04789239, source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT04789239, source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04789239-2025-07-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
- Acronym: OPRA-HF
- Condition: Heart Failure
- Condition: Hyperkalemia
- Intervention (Drug): Sodium zirconium cyclosilicate
- Intervention (Other): Placebo
- Lead sponsor: Michael Fu
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Göteborg University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Göteborg University (`cardio:org-goteborg-university`)

## Provenance

Content hash: c3ea37fa9d82828ae3c155940a102d79b1b56f1f743ea912e92c7f1d3ef67cdf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
